SCHEMBL5376944

SCHEMBL5376944

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1nc3ccccc3n1C)C(=O)N2

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.52
NTRK1 P04629 2/20 0.52
FCER2 P06734 2/20 0.52
NTRK3 Q16288 2/20 0.52
NTRK2 Q16620 2/20 0.52
SRC P12931 13/20 0.50
KDR P35968 8/20 0.49
CDK2 P24941 2/20 0.49
LCK P06239 7/20 0.47
FYN P06241 7/20 0.47
YES1 P07947 7/20 0.47
FGFR1 P11362 7/20 0.47
PDGFRB P09619 6/20 0.46
ADAMTS5 Q9UNA0 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361781 0.84 MOGAT2 (0.51) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL5365974 0.82 MAPT (0.48) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL7138017 0.80 SRC (0.52) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL5369843 0.78 SRC (0.59) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL7139377 0.78 SRC (0.51) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL5365470 0.78 SMN1; SMN2 (0.45) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL7136077 0.78 SYK (0.78) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL5370088 0.77 SRC (0.51) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL5988780 0.77 ADAMTS5 (0.48) SYKNTRK1KDRADAMTS5MEN1
SCHEMBL7137514 0.76 SYK (0.52) SYKNTRK1FCER2NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK SYK 54/4885NTRK1 223/4885FCER2 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.